Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Serplulimab (HLX10) in TNBC
NCT04301739Phase 3Not yet recruiting
- Sponsor
- Henlius
- Start
- Apr 2020
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing HLX10 Arm with Placebo Arm (2 arms). Primary endpoint: Tumor assessment up to 5 years. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04301739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301739.